Ahn Seong Joon, Kim Ko Eun, Woo Se Joon, Park Kyu Hyung
Ophthalmic Surg Lasers Imaging Retina. 2014 Mar-Apr;45(2):160-4. doi: 10.3928/23258160-20140131-03. Epub 2014 Feb 7.
Intravitreal injection of a dexamethasone implant was used to treat a 24-year-old patient with retinitis pigmentosa (RP) who developed cystoid macular edema (CME) in both eyes that was refractory to oral acetazolamide and intravitreal bevacizumab treatment. After injection, best corrected visual acuity (BCVA) improved and central macular thickness decreased, but CME recurred in both eyes 6 months later. Although a second intravitreal dexamethasone implant injection resolved the CME and improved the BCVA, CME recurred in both eyes 6 months later. The intravitreal dexamethasone implant may be useful for CME in patients with RP, but its efficacy seems to be limited over time.
玻璃体内注射地塞米松植入物用于治疗一名24岁的视网膜色素变性(RP)患者,该患者双眼出现黄斑囊样水肿(CME),对口服乙酰唑胺和玻璃体内注射贝伐单抗治疗无效。注射后,最佳矫正视力(BCVA)提高,黄斑中心厚度降低,但6个月后双眼CME复发。尽管再次玻璃体内注射地塞米松植入物使CME消退且BCVA提高,但6个月后双眼CME再次复发。玻璃体内注射地塞米松植入物可能对RP患者的CME有用,但随着时间推移其疗效似乎有限。